NASDAQ · Biotechnology

ACRV (ACRV) Stock

$2.07 -0.96% NASDAQ: ACRV Healthcare

Valuation

MetricValue
Price$2.07
Market Cap$88.60M
P/E Ratio-1.10
P/B Ratio0.99
P/S Ratio0.00
EPS (TTM)$-2.02
52-Week High$3.56
52-Week Low$1.27
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-70.14%
ROA-74.91%
ROCE-89.42%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio7.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-16.0M$-33.0M$-67.0M$-89.0M$-84.0M
Net Profit$-16.0M$-31.0M$-60.0M$-81.0M$-78.0M
EPS$-1.26$-1.42$-2.74$-2.10$-2.02
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$107.0M$181.0M$138.0M$197.0M$130.0M
Total Liabilities$130.0M$11.0M$17.0M$20.0M$17.0M
Cash$100.0M$30.0M$36.0M$40.0M$41.0M
Borrowings$6.0M$5.0M$5.0M$4.0M$3.0M

Latest News

Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit GlobeNewswire · May 21, 2026 Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · May 15, 2026 Acrivon Therapeutics Q1 Loss Narrows MT Newswires · May 13, 2026 Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts GlobeNewswire · May 13, 2026 Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities GlobeNewswire · Apr 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-14.0M$-30.0M$-43.0M$-66.0M$-64.0M
Investing Cash Flow$0$-144.0M$49.0M$-55.0M$64.0M
Financing Cash Flow$0$-3.0M$-1.0M$51.0M$-1.0M
Net Cash Flow$98.0M$-70.0M$7.0M$4.0M$2.0M
Free Cash Flow$-14.0M$-32.0M$-44.0M$-68.0M$-65.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.06
EV / EBITDA-0.62
FCF Yield-72.74%
Quick Ratio7.99
Interest Coverage0.00
Return 1Y49.61%
Return 3Y-84.57%
Return 5Y—

Ownership

Insiders Held15.55%
Institutions Held47.38%
Institutions Float Held56.10%
Institutional HolderSharesReport Date
RA Capital Management, L.P.8,340,5082026-03-31
Sands Capital Alternatives, LLC2,122,6052026-03-31
Wellington Management Group, LLP888,1302026-03-31
Acadian Asset Management. LLC845,9732026-03-31
Renaissance Technologies, LLC758,4402026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPL $325.13 +2.61% 35.78 $4.78T 0.34%
MSFT $501.02 -1.24% 27.58 $3.72T 0.73%
GOOGL $335.02 -1.28% 16.98 $4.05T 0.26%
AMZN $254.92 -1.87% 20.66 $2.74T 0.00%
META $578.54 +1.08% 21.41 $1.47T 0.36%

About ACRV

ACRV is led by CEO Peter Blume-Jensen, employs 75 people, headquartered in US, publicly traded since 2022.

ACRV stock trades at $2.07 with a market capitalization of $88.60M. The stock is valued at a price-to-earnings (P/E) ratio of -1.10, price-to-book of 0.99, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.27 and $3.56, and currently trades 41.9% below its 52-week high.

On profitability, ACRV generates a return on equity (ROE) of -70.14%, return on capital employed of -89.42%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides